{
  "docId": "019de075-e341-775b-a82c-decdaeb5c03e",
  "docSlug": "c5ed60c4cc85a094dbae2fa13cb26a34",
  "documentTitle": "Alkermes | Investor Presentation Deck | 37 slides",
  "authorId": "alkermes",
  "authorName": "Mural Oncology",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-10-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 25,
  "pageCount": 37,
  "prevPage": 24,
  "nextPage": 26,
  "slideType": "other",
  "function": "present_solution",
  "density": "balanced",
  "nDataPoints": 0,
  "notes": "The slide outlines the clinical strategy for optimizing nemvaleukin dosing, referencing specific clinical trials (ARTISTRY-3 and ARTISTRY-6).",
  "elementsJson": null,
  "metadataConfidence": 0.9,
  "imagePath": null,
  "slideHref": "/slides/019de075-e341-775b-a82c-decdaeb5c03e/25",
  "deckHref": "/decks/019de075-e341-775b-a82c-decdaeb5c03e",
  "deckJsonHref": "/decks/019de075-e341-775b-a82c-decdaeb5c03e.json",
  "deckAnchorHref": "/decks/019de075-e341-775b-a82c-decdaeb5c03e#slide-25",
  "components": [
    {
      "bbox": {
        "h": 0.5,
        "w": 0.9,
        "x": 0.05,
        "y": 0.35
      },
      "kind": "list",
      "text": "Alternative dosing options being evaluated: Explore potential broad utility; Exploring less frequent IV dosing (Days 1 and 4 Q3W; Days 1 and 8 Q3W); ARTISTRY-3 and ARTISTRY-6 studies",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "24011fe6-d566-471e-a4b1-ceeee4aadaff",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.9,
        "x": 0.05,
        "y": 0.2
      },
      "kind": "list",
      "text": "Initial IV nemvaleukin dosing regimen: 5x daily Q3W; Dosing modeled after the currently approved high-dose rhIL-2 dosing",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "442e6cd4-f35e-4e8c-b842-647f21323bbe",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.9,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "Exploration of Optimal Dose Administration and Schedule for Nemvaleukin to Establish Recommended Phase 2 Dose",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e7c9f15e-fee2-44b7-9caf-16e712f1e32d",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}